Discontinued — last reported Q3 '25
Copart Intangibles (Net) decreased by 3.9% to $57.29M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 15.8%, from $68.08M to $57.29M. Over 5 years (FY 2020 to FY 2025), Intangibles (Net) shows an upward trend with a 5.6% CAGR.
High levels reflect significant investment in growth through acquisitions; changes indicate the impact of amortization or impairment charges.
This includes the value of acquired intellectual property, such as patents, trademarks, and drug licenses, net of accumu...
Very high in the pharmaceutical industry due to the reliance on patent-protected drug portfolios.
intangible_assets_net| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $42.54M | $45.87M | $43.91M | $42.73M | $40.85M | $54.68M | $51.85M | $51.19M | $49.68M | $62.70M | $81.83M | $84.05M | $76.79M | $74.09M | $72.51M | $68.08M | $66.42M | $62.83M | $59.62M | $57.29M |
| QoQ Change | — | +7.8% | -4.3% | -2.7% | -4.4% | +33.8% | -5.2% | -1.3% | -3.0% | +26.2% | +30.5% | +2.7% | -8.6% | -3.5% | -2.1% | -6.1% | -2.4% | -5.4% | -5.1% | -3.9% |
| YoY Change | — | — | — | — | -4.0% | +19.2% | +18.1% | +19.8% | +21.6% | +14.7% | +57.8% | +64.2% | +54.6% | +18.2% | -11.4% | -19.0% | -13.5% | -15.2% | -17.8% | -15.8% |